Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty

Japanese Heart Journal

Volumn 37, Issue 3, 1996, Pages 327-332

  Lee, Young Joon ^a   Daida, Hiroyuki ^a   Yokoi, Hisashi ^a   Miyano, Hiroshi ^a   Takaya, Junshi ^a   Sakurai, Hidehiko ^a   Mokuno, Hiroshi ^a   Yamaguchi, Hiroshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Antioxidant; Lipid lowering therapy; Pravastatin; Probucol; Restenosis after PTCA

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PROBUCOL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030036185     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.37.327     Document Type: Article

References (12)

1. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cell as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369-75
2. Yokode M, Kita T, Kikawa Y, Ogorochi T, Karumiya S, Kawai C. Stimulated arachidonate metabolism during foam cell transformation of mouse peritoneal macrophages with oxidized low density lipoprotein. J Clin Invest 1988; 81: 720-29.
3. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-24.
4. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells Proc Natl Acad Sci USA 1990;.87: 5134-8.
5. Ku G, Doherty NS, Schmidt LF, Jackson RL, Dinerstein RJ. Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties. FASEB J 1990; 4: 1645-53.
6. Stiko-Rahm A, Hultgardh-Nilsson A, Regnestom J, Regnstrom J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb 1992; 12: 1099-109.
7. 125I-labeled LDL accumulation in the healing, balloon-deendothelialized rabbit aorta. Arterioscler Thromb 1992, 12: 1088-98.
8. Morel DW, Chisolm GM. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 1989; 30: 1827-34.
9. Akeron AL, Woods CW, Mosher LB, Thomas CE, Jackson RL. Inhibition of IL-1β expression in THP-1 cells by probucol and tocopherol. Atherosclerosis 1991; 86: 261-70.
10. O'Brien K, Nagano Y, Gown A, Kita T, Chait A. Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe Heritable Hyperlipidemic Rabbits. Arterioscler Thromb 1991; 11: 751-59.
11. Godfried SL, Deckelbaum LI. Natural antioxidants and restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1995; 129: 203-10.
12. Reaven PD, Parthasarathy S, Beltz WF, Wiztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992; 12: 318-24.